financetom
DARE
financetom
/
Healthcare
/
DARE
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Daré Bioscience, Inc.DARE
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States.

It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy.

The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.

Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt

Latest News >
National Bank Reviews Manulife Financial's Q3
National Bank Reviews Manulife Financial's Q3
Nov 9, 2024
11:56 AM EST, 11/07/2024 (MT Newswires) -- Manulife Financial's ( MFC ) third quarter results exceeded expectations on the back of strong Asia and WAM segment growth (and equally strong sales performance), notes National Bank. Analyst Gabriel Dechaine says these businesses are critical drivers for the lifeco to achieve its 18% ROE by 2027 target. Separately, the company executed on...
Tapestry Stock Jumps On Q3 Earnings Beat, Strong Sales, Raised Guidance
Tapestry Stock Jumps On Q3 Earnings Beat, Strong Sales, Raised Guidance
Nov 9, 2024
Tapestry, Inc ( TPR ). reported its fiscal 2025 first-quarter financial results on Thursday before the market opened. Here’s what you need to know. What To Know: Tapestry posted adjusted earnings per share of $1.02, beating the consensus estimate of 95 cents, according to Benzinga Pro. The Coach and Kate Spade parent company reported revenue of $1.51 billion, beating estimates...
Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals
Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals
Nov 9, 2024
Ralph Lauren Corporation ( RL ) shares surged after the company reported better-than-expected second-quarter results. Quarterly adjusted earnings per share of $2.54, topped the consensus of $2.41. Quarterly revenues of $1.726 billion beat the street view of $1.677 billion. Revenue grew 6% YoY on a reported basis and rose 6% in constant currency. Foreign currency contributed 10 basis points to...
Market Chatter: Nippon Steel Seeks to Finalize $15 Billion US Steel Deal by Year-End
Market Chatter: Nippon Steel Seeks to Finalize $15 Billion US Steel Deal by Year-End
Nov 9, 2024
11:18 AM EST, 11/07/2024 (MT Newswires) -- Nippon Steel continues to anticipate closing its $15 billion acquisition of United States Steel ( X ) by year-end, aiming to sidestep any potential opposition once President-elect Donald Trump returns to the White House in January, Reuters reported Thursday, citing Nippon Steel's Vice Chairman Takahiro Mori. The transaction, which Nippon Steel considers essential...
Copyright 2023-2025 - www.financetom.com All Rights Reserved